Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046874 | PMC |
| http://dx.doi.org/10.1016/j.jaccao.2025.02.002 | DOI Listing |
Publication Analysis
Top Keywords
reply enalapril
4
enalapril preventing
4
preventing cardiotoxicity
4
cardiotoxicity high-dose
4
high-dose anthracycline
4
anthracycline therapy
4
therapy breast
4
breast cancer
4
cancer lymphoma
4
lymphoma patients
4
Similar Publications
Reply: Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients.
JACC CardioOncol
April 2025
The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlebrough, United Kingdom.
Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
J Med Econ
December 2018
a Agency for Care Effectiveness , Ministry of Health , Singapore.
In reply to: Enalapril and the VEGFA gene: personalized medicine in hypertension therapy.
Eur J Clin Pharmacol
January 2016
Department of Pharmacology, Ribeirao Preto Medical School, University of Sao Paulo, Av. Bandeirantes, 3900, Ribeirao Preto, SP, 14049-900, Brazil.